There are two perspectives into which the positive opinions on Omnitrope and Valtropin need to be placed.
The first is the sobering thought that hGH is one of the simplest, smallest and best-characterized recombinant proteins in medicine today. Although the EMEA has undoubtedly erred on the side of caution in considering the precedent-setting Omnitrope application, Sandoz had to jump through an awful lot of regulatory hoops to get approval. It seems very unlikely that the EMEA will lower the bar very much for purveyors of copies of more complex proteins, such as interferon or erythropoietin, or antibodies. Human growth hormone has no glycosylation sites and hence no possibility of being produced in differently glycosylated variants. Molecules such as erythropoietin and alpha interferon are glycosylated on multiple sites. A typical antibody molecule has over a thousand chiral centers, billions of enantiomers and extensive glycosylation as well as other post-translation modifications. Biogeneric versions will probably not show sufficient chemical and in vitro similarity to be exempted from a full testing requirement.
In this light, the business case for biogenerics is looking less attractive. Copying a brand protein not only requires an enormous reverse engineering effort (often with scant knowledge of the brand manufacturer's master cell line, fermentation method or purification procedure), but also experience and know-how in protein manufacture and process quality. If costly and large-scale clinical testing in humans is also required, launch costs are going to be high and it may be difficult significantly to undercut the price of brand products. Under the present regulatory regime, therefore, there is a very strong likelihood that copies of biopharmaceuticals in Europe will not be substantially cheaper than the original brand. Biogeneric manufacturers will, in essence, be marketing 'me-too' protein products at 'me-first' prices. And that is going to make it pretty difficult to dislodge the market incumbents.
Despite all these difficulties, at least Europe now has some competition in its biologics markets. This is decidedly not the case in the United States, allegedly the home of competition and the land of the free market. In America, biogenerics appear to be about as welcome as a cold sore on a first date. Despite assurances to Orrin Hatch (Republican-UT) in a Senate hearing in August 2004 that it would act on this issue, the US Food and Drug Administration has continued to tiptoe around (some might say drag its feet) on biogenerics regulation. A white paper on biogenerics promised in 2005 has never materialized. In the meantime, the top ten biotech companies-with their combined 84% share of the protein drug market-are essentially enjoying a second monopoly (to follow their patent monopoly) following expiry of their intellectual property. This is unacceptable. Even if biogenerics are not going to be the solution to the US healthcare system's financial woes, at least the American people should be given the opportunity to benefit from a greater choice of medicines.
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